Blood Krebs von den Lungen-6 levels predict treatment response to antifibrotic therapy in patients with idiopathic pulmonary fibrosis

Table 3 Logistic regression analysis for DP in IPF patients with high baseline KL-6 levels (≥ 500 U/mL)

Variables	Unadjusted			Multivariable (adjusted by age and FVC)
Variables	Odds ratio	95% CI	P-value	Odds ratio	95% CI	P-value
Age	1.061	1.004–1.122	0.037	–	–	–
Male sex	0.900	0.374–2.164	0.813	–	–	–
Ever-smoker	0.776	0.329–1.828	0.562	–	–	–
BMI, kg/m²	0.827	0.720–0.949	0.007	0.841	0.734–0.963	0.012
FVC, % predicted	0.963	0.937–0.990	0.007	–	–	–
DLco, % predicted	0.988	0.966–1.011	0.296	–	–	–
TLC, % predicted	0.971	0.934–1.009	0.130	–	–	–
6MWT, distance, m	0.993	0.990–0.997	0.001	0.995	0.991–0.999	0.019
6MWT, SpO2, %	0.975	0.918–1.036	0.421	–	–	–
Baseline KL-6	1.000	1.000–1.001	0.576	–	–	–
Δ KL-6 (absolute), U/mL	1.003	1.000–1.006	0.036	1.003	1.000–1.006	0.058
Δ KL-6 (relative), %	1.042	1.005–1.081	0.026	1.043	1.005–1.084	0.028

DP: disease progression; CI: confidence interval; BMI: body mass index; FVC: forced vital capacity; DLco: diffusing capacity of the lung for carbon monoxide; TLC: total lung capacity; 6MWT: 6-minute walk test; KL-6: Krebs von den Lungen-6; and Δ: changes from baseline for 1 month

ISSN: 1465-993X